Amicus Therapeutics Inc. (NASDAQ:FOLD) Q1 2023 Earnings Conference Call May 10, 2023 8:30 AM ET

Company Participants

Bradley Campbell - President, Chief Executive Officer

Sébastien Martel - Chief Business Officer

Jeff Castelli - Chief Development Officer

Daphne Quimi - Chief Financial Officer

Andrew Faughnan - Vice President, Investor Relations

Conference Call Participants

Malcolm Kuno - JP Morgan

Ellie Merle - UBS

Joseph Schwartz - SVB Securities

Athena - Cowen

Dae Gon Ha - Stifel

Kristen Kluska - Cantor Fitzgerald

Shrinatra - Goldman Sachs

Jeff Hung - Morgan Stanley

Zhiqiang Shu - Berenberg

Operator

Good morning ladies and gentlemen and welcome to the Amicus Therapeutics first quarter 2023 financial results conference call and webcast.

At this time, all participants are in a listen-only mode. Later we will conduct a question and answer session and instructions will follow at that time. As a reminder, this conference call is being recorded.

I would now like to turn the conference over to your host, Mr. Andrew Faughnan, Vice President of Investor Relations. You may begin.

Andrew Faughnan

Good morning, thank you Gigi.

Thank you for joining our conference call to discuss Amicus Therapeutics first quarter 2023 financial results and corporate highlights. Leading today’s call, we have Bradley Campbell, President and Chief Executive Officer; Daphne Quimi, Chief Financial Officer; Sébastien Martel, Chief Business Officer; and Dr. Jeff Castelli, Chief Development Officer. Joining for Q&A is Dr. Mitchell Goldman, Chief Medical Officer, and Ellen Rosenberg, Chief Legal Officer.

As referenced on Slide 2, we may make forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 relating to our business, as well as our plans and prospects. Our forward-looking statements should not be regarded as representation by us that any of our plans will be achieved. Any or all of the forward-looking statements made on this call may turn out to be wrong and can be affected by inaccurate assumptions we might make, or by known or unknown risks and uncertainties. You are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and we undertake no obligation to revise or update this presentation and conference call to reflect or circumstances after the date hereof.

For a full discussion of such forward-looking statements and the risks and uncertainties that may impact them, we refer you to the forward-looking statements and risk factors section of our annual report on Form 10-K for the year ended December 31, 2022, and the quarterly report on Form 10-Q for the quarter ended March 31, 2023, to be filed later today with the Securities and Exchange Commission.